Evidence map›Paper›PMID 30171426›Full record

ArticleCytotechnology2018

Rhaponticum carthamoides transformed root extract inhibits human glioma cells viability, induces double strand DNA damage, H2A.X phosphorylation, and PARP1 cleavage.

Ewa Skała, Monika Toma, Tomasz Kowalczyk, Tomasz Śliwiński, Przemysław Sitarek

Abstract read
In one paragraph

Article in Cytotechnology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Frontiers in pharmacology · 2026
    Review
  3. Phytochemical and Anti-Ischemic Stroke Properties from theDrug design, development and therapy · 2026
    Review
  4. Article
  5. Review
  6. Epigenetic effects of herbal medicine.Clinical epigenetics · 2023
    Review
  7. Review
  8. Therapeutic potential of natural products in glioblastoma treatment: targeting key glioblastoma signaling pathways and epigenetic alterations.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020
    Review
  9. Oxidative medicine and cellular longevity · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ewa SkałaDepartment of Biology and Pharmaceutical Botany, Medical University of Łódź, Muszyńskiego 1, 90-151, Łódź, Poland. ewa.skala@umed.lodz.pl.
Monika TomaLaboratory of Medical Genetics, Faculty of Biology and Environmental Protection, University of Łódź, Pomorska 141/143, 90-236, Łódź, Poland.
Tomasz KowalczykDepartment of Genetics, Plant Molecular Biology and Biotechnology, Faculty of Biology and Environmental Protection, University of Łódź, Banacha 12/16, 90-237, Łódź, Poland.
Tomasz ŚliwińskiLaboratory of Medical Genetics, Faculty of Biology and Environmental Protection, University of Łódź, Pomorska 141/143, 90-236, Łódź, Poland.
Przemysław SitarekDepartment of Biology and Pharmaceutical Botany, Medical University of Łódź, Muszyńskiego 1, 90-151, Łódź, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rhaponticum carthamoides transformed root extract induces double strand DNA damage by increasing the number of phosphorylated H2A.X- and cleaved PARP1-positive U87MG cells and patient-derived IV grade glioma cells. Furthermore, treatment of these cells with root extract causes down-regulation of UHRF1 and DNMT1. Transformed root extract is rich in caffeoylquinic acid derivatives, especially tricaffeoylquinic acid derivatives. Our findings demonstrate that the R. carthamoides transformed root extract may trigger apoptosis in glioma cells by induction of DNA damage, PARP cleavage and epigenetic modification.

Indexed as

Caffeoylquinic acid derivativesGlioma cellsH2A.X phosphorylationPARP1 cleavageRhaponticum carthamoidesTransformed roots

Identifiers

PMID30171426
PMCPMC6269353

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.